# Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

> **NCT00684294** · PHASE1 · TERMINATED · sponsor: **Mary Crowley Medical Research Center** · enrollment: 46 (actual)

## Conditions studied

- Carcinoma, Advanced Metastatic

## Interventions

- **BIOLOGICAL:** TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine

## Key facts

- **NCT ID:** NCT00684294
- **Lead sponsor:** Mary Crowley Medical Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05-27
- **Primary completion:** 2009-05
- **Final completion:** 2019-05-28
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Since no safety issues have been reported to date in association with TAG vaccine, no further survival follow-up will be done.
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684294, "Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00684294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*